Targets › PARP5B
1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Mar 2027.
Poly-ADP-ribosyltransferase involved in various processes such as Wnt signaling pathway, telomere length and vesicle trafficking. Acts as an activator of the Wnt signaling pathway by mediating poly-ADP-ribosylation of AXIN1 and AXIN2, 2 key components of the beta-catenin destruction complex: poly-ADP-ribosylated target proteins are recognized by RNF146, which mediates their ubiquitination and subsequent degradation. (UniProt, Q9H2K2)
Open in Phaseline: the race on PARP5B, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Eiji Shinozaki | RK-582 Tankyrase (PARP-5a/b) inhibitor | PARP5A, PARP5B | Phase 1 | Unresectable Colorectal Neoplasm Metastasis | Mar 2027 |
Unresectable Colorectal Neoplasm Metastasis (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.